CASI Pharmaceuticals (CASIF) Research & Development (2022 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Research & Development came in at $1.2 million in Q4 2025, down 94.66% YoY from $23.1 million in Q4 2024, and up 187.4% on a QoQ basis from -$1.4 million in Q3 2025.
CASI Pharmaceuticals (CASIF) Research & Development (2022 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 4 years of Research & Development data on file, last reported at $1.2 million in Q4 2025.
- Quarterly Research & Development fell 94.66% year-over-year to $1.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.8 million (down 121.48% YoY) and the FY2025 annual result came in at $6.3 million, down 64.69% from the prior year.
- Research & Development improved to $1.2 million in Q4 2025, from -$1.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $23.1 million in Q4 2024 to a low of -$27.7 million in Q4 2022.
- A 4-year average of $905125.0 and a median of $1.8 million in 2023 frame the typical range for Research & Development.
- The widest YoY moves for Research & Development: up 159.65% in 2024, down 197.71% in 2024.
- Tracing CASIF's Research & Development over 4 years: stood at -$27.7 million in 2022, then jumped by 132.09% to $8.9 million in 2023, then soared by 159.65% to $23.1 million in 2024, then sank by 94.66% to $1.2 million in 2025.
- The last three Research & Development figures came in at $1.2 million (Q4 2025), -$1.4 million (Q3 2025), and -$1.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Sep 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.72 Mn |
| Mar 31, 2025 | -1.94 Mn |
| Dec 31, 2024 | 23.12 Mn |
| Sep 30, 2024 | -1.52 Mn |
| Jun 30, 2024 | -1.25 Mn |
| Mar 31, 2024 | -2.48 Mn |
| Dec 31, 2023 | 8.90 Mn |
| Sep 30, 2023 | 2.40 Mn |
| Jun 30, 2023 | 2.61 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | -27.74 Mn |
| Sep 30, 2022 | 3.91 Mn |
| Jun 30, 2022 | 3.85 Mn |
| Mar 31, 2022 | 3.99 Mn |